Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;3(2):133-9.
Epub 2010 Jun 12.

Bioenergetics breakdown in Alzheimer's disease: targets for new therapies

Affiliations

Bioenergetics breakdown in Alzheimer's disease: targets for new therapies

Uday Saxena. Int J Physiol Pathophysiol Pharmacol. 2011.

Abstract

Alzheimer's disease is rapidly growing worldwide and yet there is no cure for it. Currently available drugs only provide symptomatic relief and do not intervene in disease process sufficiently enough to prevent or cure it. Characteristic features of this disease are decline in neuronal mass and cognitive functions. The most dominant hypothesis proposed for pathogenesis of this disease is called "amyloid hypothesis". It states that excessive production of amyloid peptides called abeta peptides (Aβ) is the underlying cause of neuronal death and dysfunction. However, recent drugs designed based on amyloid hypothesis have failed in clinical trails, demanding fresh assessment. Early and persistent molecular events in this disease progression are energy deficiency and high oxidative stress in the neurons. Our review will put together a disease model based on known human and animal data with regards to breakdown in neuronal energy generation. The model will integrate energy deficits as the cause of neuronal dysfunction and abeta peptide production culminating in catastrophic loss of cognitive functions. Finally, based on this model, we will also suggest enzyme targets in neuronal bioenergetics pathway for design and development of new disease modifying therapies.

Keywords: Alzheimer's disease; amyloid hypothesis; neuronal energy; new therapeutics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Amyloid hypothesis of Alzheimer's Disease. The classic amyloid hypothesis cascade of events is shown here. The main features are overproduction of Aβ peptides by secretase cleavage, peptide aggregation followed by neurotoxicity, tau phosphorylation, plaque and neurofibrillary tangle (NFT) formation with end result of cognitive loss and Alzheimer's disease.
Figure 2
Figure 2
Bioenergetics of neurodegeneration model (BEND model). An “energy deprivation” based model of Alzheimer's is proposed. The model states that known disease risk factors trigger molecular pathways, which leads to decrease in enzyme activities important in cellular energy generation. Energy defects can result in neuronal dysfunction/loss, BACE-1 induction and cognitive decline.

References

    1. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20:154–159. - PubMed
    1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766. - PubMed
    1. Saxena U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Expert Opinion Therapeutic Targets. 2010;14(12):1273–1277. - PubMed
    1. De Strooper B, Vassar R, Golde T. The secreta-ses: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99–107. - PMC - PubMed
    1. Struble RG, Ala T, Patrylo PR, Brewer GJ, Yan XX. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis. 2010;22(2):393–399. - PMC - PubMed

LinkOut - more resources